
What smart money is saying about M3
1 fund in our archive has pitched M3 — most recently Harding Loevner International Small Companies Equity in June 2026.
M3, Inc. is a Japanese company that delivers a broad spectrum of internet-based services, predominantly catering to medical professionals and the broader healthcare industry. Its operations are segmented into five key areas: Medical Platform, Evidence Solution, Career Solution, Site Solution, and Overseas. M3 manages several specialized online platforms, including m3.com, an exclusive information portal for healthcare professionals; MR-kun, which ensures member doctors receive ongoing updates via the m3com platform; QOL-kun, offering non-medical life support; and AskDoctors, where certified physicians address public health inquiries from the general public. Internationally, it operates MDLinx for U.S. medical professionals and Doctorsnetuk, a U.K.-based site supporting pharmaceutical companies and providing drug information databases across France, Germany, and Spain. Furthermore, M3 offers dedicated career services for doctors and pharmacists through its m3com CAREER platform. Its diverse business portfolio extends to sales and marketing for pharmaceutical and medical device companies, as well as the development, sale, and maintenance of electronic medical records and equipment for healthcare facilities. M3 also conducts surveys for medical professionals, offers online sales and marketing assistance to pharmaceutical firms, provides management consulting to medical institutions, delivers home-visit nursing services, and specializes in human resource solutions for healthcare staff, alongside managing clinical trial facilities. Established in 2000, the company was initially named So-netM3, Inc., before rebranding to M3, Inc. in January 2010. Its headquarters are located in Tokyo, Japan.
Position history
Every position in M3 on record in the archive was reported in Q2 2026, across 1 fund letter — 1 opened or added to the position.
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q2 2026 | 1 | 1 | 0 | 1 |
Fund activity · 1 position · 1 move
- June 2026
“Earlier in the year, we also purchased Rakus and M3, both of which had been weighed down by concerns over AI disruption that appear to be overblown.”
Read the letterM3
Also mentioned · 1
These funds discuss M3 — as a competitor, benchmark or comparable — without disclosing a position in it.
- MentionedHL International EquityMay 2026
“In Japan, medical information platform M3 declined amid growing concerns that generative AI could disrupt its core medical information and pharmaceutical marketing businesses.”
Read the letterM3
Fund coverage · 1 thesis
M3 runs a physician information platform with an unrivaled ecosystem in Japan, strong data advantages, and AI that may reinforce personalization and engagement.
Read the full thesis
Read every full thesis on M3
Unlock all 1 thesis — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→